The authors went on to show that combinations of XL147 with HER2 antagonists (trastuzumab or lapatinib) were synergistic in delaying tumour growth in mice bearing xenografts derived from BT474, a HER2+/PIK3CA-mutant BC cell line. Here, PIK3CA is linked to neoplasm.